Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-07-10 Sale |
2023-07-10 5:01 pm |
Adaptimmune Therapeutics PLC | ADAP | Menzel Garry E Director |
47,702 | $0.9108 | $43,447 | 75,056 (Direct) |
View |
| 2023-06-01 Sale |
2023-06-01 4:22 pm |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
404,330 | $0 | $0 | 0 (Indirect Direct) |
View |
| 2022-12-09 Sale |
2022-12-13 8:19 pm |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
31,938 | $1.0969 | $35,034 | 575,139 (Indirect Direct) |
View |
| 2022-12-07 Sale |
2022-12-09 4:44 pm |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
18,425 | $1.2678 | $23,360 | 625,502 (Indirect Direct) |
View |
| 2022-12-05 Sale |
2022-12-07 7:56 pm |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
23,416 | $1.3574 | $31,784 | 667,343 (Indirect Direct) |
View |
| 2022-12-02 Sale |
2022-12-05 7:49 pm |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
8,408 | $1.39 | $11,687 | 519,635 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-07-01 Option Award |
2024-07-01 5:03 pm |
2025-07-01 2034-07-01 |
Adaptimmune Therapeutics PLC | ADAP | Menzel Garry E Director |
1,121,604 | $0 | 1,121,604 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 4:21 pm |
N/A 2034-06-04 |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
7,639 | $0 | 7,639 (Direct) |
View |
| 2024-06-06 Option Award |
2024-06-06 5:54 pm |
N/A 2034-06-05 |
Black Diamond Therapeutics Inc. | BDTX | Menzel Garry E Director |
30,550 | $0 | 30,550 (Direct) |
View |
| 2023-07-05 Option Award |
2023-07-05 5:00 pm |
N/A 2024-03-15 |
Adaptimmune Therapeutics PLC | ADAP | Menzel Garry E Director |
10,848,678 | $0 | 10,848,678 (Direct) |
View |
| 2023-07-03 Option Award |
2023-07-03 5:03 pm |
2024-07-03 2033-07-03 |
Adaptimmune Therapeutics PLC | ADAP | Menzel Garry E Director |
981,463 | $0 | 981,463 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-15 6:25 pm |
N/A 2033-06-12 |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
19,441 | $0 | 19,441 (Direct) |
View |
| 2023-06-01 Option Award |
2023-06-01 4:59 pm |
N/A N/A |
Adaptimmune Therapeutics PLC | ADAP | Menzel Garry E Director |
611,224 | $0 | 410,578 (Indirect) |
View |
| 2023-05-16 Option Award |
2023-05-17 9:08 pm |
N/A 2033-05-15 |
Black Diamond Therapeutics Inc. | BDTX | Menzel Garry E Director |
16,500 | $0 | 16,500 (Direct) |
View |
| 2022-12-15 Option Award |
2022-12-19 5:32 pm |
N/A 2032-12-14 |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
277,689 | $0 | 682,019 (Direct) |
View |
| 2022-12-01 Exercise |
2022-12-05 7:49 pm |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
442,116 | $0 | 519,635 (Direct) |
View |
| 2022-11-17 Option Award |
2022-11-18 4:56 pm |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
262,584 | $0 | 528,043 (Direct) |
View |
| 2022-07-05 Gift |
2022-08-26 4:30 pm |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
265,459 | $0 | 132,730 (Indirect) |
View |
| 2022-06-10 Option Award |
2022-06-13 7:04 pm |
N/A 2032-06-09 |
Black Diamond Therapeutics Inc. | BDTX | Menzel Garry E Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-08 5:00 pm |
N/A 2032-06-06 |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-02-28 Option Award |
2022-03-18 4:24 pm |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
1,425 | $2.3 | 265,459 (Direct) |
View |
| 2021-12-10 Exercise |
2021-12-10 4:32 pm |
N/A 2026-12-12 |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
350,000 | $0.74 | 707,865 (Direct) |
View |
| 2021-12-09 Option Award |
2021-12-10 4:32 pm |
N/A 2031-12-08 |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
305,800 | $0 | 707,865 (Direct) |
View |
| 2021-08-31 Option Award |
2021-12-10 4:32 pm |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President & CEO |
422 | $14.26 | 707,865 (Direct) |
View |
| 2021-06-08 Option Award |
2021-06-25 5:01 pm |
N/A 2031-06-07 |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
11,650 | $0 | 11,650 (Direct) |
View |
| 2021-06-18 Option Award |
2021-06-22 6:15 pm |
N/A 2031-06-17 |
Black Diamond Therapeutics Inc. | BDTX | Menzel Garry E Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2021-04-20 Option Award |
2021-04-23 9:14 pm |
N/A 2031-04-19 |
Black Diamond Therapeutics Inc. | BDTX | Menzel Garry E Director |
14,921 | $0 | 14,921 (Direct) |
View |
| 2020-08-31 Option Award |
2021-03-08 08:16 am |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
1,132 | $10.1 | 88,612 (Direct) |
View |
| 2021-02-28 Option Award |
2021-03-08 08:16 am |
N/A N/A |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
686 | $16.12 | 88,612 (Direct) |
View |
| 2020-08-13 Option Award |
2021-01-27 5:19 pm |
N/A 2030-08-13 |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
29,555 | $0 | 29,555 (Direct) |
View |
Ownership |
2021-01-27 5:17 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Menzel Garry E Director |
0 | $0 | 0 (Direct) |
View |
| 2020-12-10 Option Award |
2020-12-11 06:17 am |
N/A 2030-12-09 |
TCR2 THERAPEUTICS INC. | TCRR | Menzel Garry E President and CEO |
245,000 | $0 | 331,794 (Direct) |
View |